Cluster immunotherapy - Inmunotek/ROXALL Medizin GmbH

Drug Profile

Cluster immunotherapy - Inmunotek/ROXALL Medizin GmbH

Alternative Names: Alxoid; Clustek; Cluster-allergoid - ROXALL Medizin GmbH; CLUSTOID; CLUSTOID® Wiesenlieschgras; CLUSTOID® Timothy; Glutaraldehyde polymerised allergen extract - ROXALL Medizin GmbH; Roxoid

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator Inmunotek
  • Developer Inmunotek; ROXALL Medizin GmbH
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis

Most Recent Events

  • 15 May 2014 ROXALL initiates enrolment in a phase II trial for Allergic rhinitis (In adults, In the elderly) in Germany (SC) (EudraCT2010-022083-12)
  • 01 Dec 2009 ROXALL completes a phase III trial in Allergic rhinitis (In adults, In the elderly) in Germany (SC) (NCT01012531)
  • 01 Oct 2008 Phase-III clinical trials in Allergic rhinitis (In adults, In the elderly) in Germany (SC) (NCT01012531)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top